|Table of Contents|

eIF4E Promotes Drug Resistance in Non-small Cell Lung Carcinoma(PDF)

《南京师范大学学报》(自然科学版)[ISSN:1001-4616/CN:32-1239/N]

Issue:
2014年02期
Page:
91-
Research Field:
生命科学
Publishing date:

Info

Title:
eIF4E Promotes Drug Resistance in Non-small Cell Lung Carcinoma
Author(s):
Li MinChen XiMa ZhuoWu DandanNi PingZhai SulanLi PingZou MeijuanWang Xuerong
Department of Pharmacology,School of Medicine,Nanjing Medical University,Nanjing 210029,China
Keywords:
NSCLCeIF4Eerlotinibdrug resistanceEGFR
PACS:
R965. 2;R734. 2
DOI:
-
Abstract:
To observe the effects of eIF4E on the proliferation of erlotinib resistant cells and mechanism. Paired erlotinib sensitive and resistant HCC827-EP and HCC827-ER cells were used. Protein and mRNA expression levels were detected by Western blot and quantitative RT-PCR. The 5 ds growth curve and inhibition effects of erlotinib were determined by SRB assay. Downregulation of eIF4E expression were achieved by transfection of cells with siRNA targeting eIF4E using lipofectamine,and nonsense siRNA were used as control. eIF4E expression was increased in HCC827-ER cells compared with HCC827-EP cells. And downregulation of eIF4E expression inhibited the growth of HCC827-ER cells(P<0. 05)and sensitized their reponses erlotinib possibly through downregualtion of eIF4E expression( P <0. 05). Downregulation of eIF4E expression inhibited the growth of NSCLCs and enhanced the inhibitory effects of erlotinib.

References:

[1]Jemal A,Siegel R,Ward E,et al. Cancer statistics,2008[J]. CA:A Cancer Journal for Clinicians,2008,58(2):71-96.
[2] Ferlay J,Shin H R,Bray F,et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[ J]. International Journal of Cancer,2010,127(12):2893-2917.
[3] Kosaka T,Yamaki E,Mogi A,et al. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer[J/ OL]. BioMed Research International,2011:7[2011-04-11]. http:/ / dx. doi. org/10. 1155/2011/165214.
[4] Cappuzzo F,Ciuleanu T,Stelmakh L,et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer:a mul-ticentre,randomised,placebo-controlled phase 3 study[J]. The Lancet Oncology,2010,11(6):521-529.
[5] Goodfellow I G,Roberts L O. Eukaryotic initiation factor 4E[J]. The International Journal of Biochemistry and Cell Biology, 2008,40(12):2 675-2 680.
[6] De Benedetti A,Graff J R. eIF-4E expression and its role in malignancies and metastases[J]. Oncogene,2004,23(18):3 189-3 199.
[7] Graff J R,Konicek B W,Carter J H,et al. Targeting the eukaryotic translation initiation factor 4E for cancer therapy[ J]. Cancer Research,2008,68(3):631-634.
[8] Thumma S C,Kratzke R A. Translational control:a target for cancer therapy[J]. Cancer Letters,2007,258(1):1-8.
[9] Ma Z,Zhu L,Luo X,et al. Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3βin NSCLC cells[J].Cancer Biology and Therapy,2012,13(11):1 009-1 017.
[10] Mathis J M, Willians B J, Sibley D A, et al. Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control[J]. The Journal of Gene Medicine,2006,8(9):1 105-1 120.
[11] Nowak D E,Tian B,Jamaluddin M,et al. RelA Ser276 phosphorylation is required for activation of a subset of NF-κB-dependent genes by recruiting cyclin-dependent kinase 9/ cyclin T1 complexes[J]. Molecular and Cellular Biology,2008,28(11):3 623-3 638.
[12] Zhou B B S,Peyton M,He B,et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer[J]. Cancer Cell,2006,10(1):39-50.
[13] Pao W,Miller V A,Politi K A,et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J]. PLoS Medicine,2005,2(3):e73.
[14] Chen G,Kronenberger P,Teugels E,et al. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents[ J]. Biochemical and Biophysical Research Communications,2013,431(3):623-629.
[15] Maheswaran S, Sequist L V, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells[ J]. New England Journal of Medicine,2008,359(4):366-377.
[16] Kobayashi S,Boggon T J,Dayaram T,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J]. New England Journal of Medicine,2005,352(8):786-792.
[17] Rosenwald I B. The role of translation in neoplastic transformation from a pathologist爷s point of view[J]. Oncogene,2004,23 (18):3 230-3 247.
[18] Coqueret O. Linking cyclins to transcriptional control[J]. Gene,2002,299(1):35-55.
[19] Inaba T,Matsushime H,Valentine M,et al. Genomic organization,chromosomal localization,and independent expression of human cyclin D genes[J]. Genomics,1992,13(3):565-574.

Memo

Memo:
-
Last Update: 2014-06-30